{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958540",
  "id": "02958540",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250616",
  "time": "0846",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krxjf8fgcshq.pdf",
  "summary": "**Clinical Trial Update Summary:**  \n\n- **Safety Review Outcome:** No safety concerns or dose-limiting toxicities observed in Phase I trial's first four cohorts; clearance granted for **Cohort 5** dosing.  \n- **Trial Protocol Adjustment:** Expanded to **6 cohorts** with higher doses/longer infusion duration; final data expected by **September 2025 quarter**.  \n- **Previous Preclinical Results:**  \n  - **Neuroprotection:** 42% brain tissue rescue in stroke models (Feb 2024), significant TBI protection (Apr 2025).  \n  - **Cardioprotection:** 86% efficacy in myocardial injury (Oct 2024), 42% with 3-hour infusion (May 2025).  \n\n**Key Takeaway:** Positive safety progression supports continued clinical development; no material financial/capital impact disclosed.  \n\n*Omitted:* Background on TRPC inhibitors, historical trial details, Appendix 1 protocol specifics (non-material to trading).",
  "usage": {
    "prompt_tokens": 2074,
    "completion_tokens": 201,
    "total_tokens": 2275,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:55:21.721322"
}